查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703468

僵直性脊椎炎治療市場－全球產業規模、佔有率、趨勢、機會和預測（按藥物、最終用途、地區和競爭細分，2020-2030 年）

Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By End Use, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球僵直性脊椎炎 (AS) 治療市場價值為 51 億美元，預計在預測期內將出現強勁成長，到 2030 年年複合成長率(CAGR) 為 7.45%。

市場概覽
預測期 2026-2030
2024年市場規模 51億美元
2030年市場規模 78.7億美元
2025-2030 年複合年成長率 7.45%
成長最快的領域 修美樂
最大的市場 北美洲

僵直性脊椎炎是一種慢性發炎性自體免疫疾病，主要影響脊柱，導致持續疼痛、僵硬和活動能力下降。僵直性脊椎炎屬於脊椎關節炎疾病，也可影響周邊關節和各種器官。近年來，由於臨床研究的進步、新型治療方式的引入以及全球對該疾病認知的提高，AS 治療市場取得了顯著進展。

僵直性脊椎炎的特徵是薦髂關節發炎，薦髂關節連接脊椎底部的薦骨和骨盆。隨著時間的推移，這種發炎會導致脊椎融合，嚴重限制脊椎的靈活性並改變姿勢。常見症狀通常表現在成年早期，包括下背痛和晨僵。及時診斷和有效的疾病管理對於提高患者的生活品質至關重要。

僵直性脊椎炎是一個全球性的健康問題，影響著全世界數百萬人。發病率因地區和人群而異，遺傳因素（尤其是 HLA-B27 基因）在疾病發展中起著重要作用。近年來，由於早期診斷、治療的可及性提高以及先進治療方法的出現，AS 治療市場得到了大幅擴張。

關鍵市場促進因素

僵直性脊椎炎盛行率上升

早期診斷 AS 的能力使得早期介入成為可能，從而增強了長期治療的依從性並推動了對治療產品的持續需求。

主要市場挑戰

認知有限，診斷延遲

主要市場趨勢

診斷和治療技術的進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：僵直性脊椎炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物分類（Cosentyx、Humira、Simponi、Remicade、Enbrel、Cimzia）
    • 依最終用途（醫院、診所、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美僵直性脊椎炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲僵直性脊椎炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太僵直性脊椎炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美洲僵直性脊椎炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲僵直性脊椎炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球僵直性脊椎炎治療市場：SWOT 分析

第 14 章：競爭格局

  • AbbVie, Inc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • UCB, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16738

Global Ankylosing Spondylitis (AS) therapeutics market was valued at USD 5.10 billion in 2024 and is expected to witness robust growth during the forecast period, registering a compound annual growth rate (CAGR) of 7.45% through 2030.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.10 Billion
Market Size 2030USD 7.87 Billion
CAGR 2025-20307.45%
Fastest Growing SegmentHumira
Largest MarketNorth America

Ankylosing spondylitis is a chronic, inflammatory autoimmune disorder that predominantly affects the spine, leading to persistent pain, stiffness, and reduced mobility. Classified within the group of spondyloarthritis disorders, AS can also involve peripheral joints and various organs. The market for AS therapeutics has experienced notable progress in recent years, fueled by advancements in clinical research, the introduction of novel treatment modalities, and increased global awareness of the disease.

AS is marked by inflammation of the sacroiliac joints, connecting the sacrum at the base of the spine to the pelvis. Over time, this inflammation can result in the fusion of spinal vertebrae, severely limiting spinal flexibility and altering posture. Typically manifesting in early adulthood, common symptoms include lower back pain and morning stiffness. Timely diagnosis and effective disease management are essential to enhancing patients' quality of life.

Ankylosing spondylitis is a global health concern, affecting millions of individuals worldwide. Prevalence rates vary by region and population, with genetic factors-particularly the HLA-B27 gene-playing a major role in disease development. The AS therapeutics market has expanded considerably in recent years due to earlier diagnoses, increased treatment accessibility, and the availability of advanced therapeutics.

Key Market Drivers

Rising Prevalence of Ankylosing Spondylitis

The increasing global incidence of ankylosing spondylitis is a primary driver of market growth. Although AS affects a relatively small proportion of the population-ranging from 0.1% to 1.4%-its impact is significant, particularly among males and individuals in their most productive working years, often beginning in their mid-20s.

This growing patient base is intensifying the demand for effective, long-term therapeutic solutions, creating ample opportunities for pharmaceutical manufacturers and healthcare providers. Traditionally underdiagnosed due to its insidious onset and nonspecific symptoms, AS is now being identified earlier thanks to heightened awareness and advancements in diagnostic imaging technologies.

The ability to diagnose AS in its early stages enables earlier intervention, which enhances long-term treatment adherence and drives sustained demand for therapeutic products.

Key Market Challenges

Limited Awareness and Delayed Diagnosis

One of the core challenges faced by the AS therapeutics market is the limited awareness among both healthcare professionals and the general public. Misdiagnosis or late diagnosis remains a common issue, often resulting in delayed treatment and worsened patient outcomes. Addressing this gap through education and awareness campaigns is vital to improving early detection and disease management.

Key Market Trends

Technological Advancements in Diagnosis and Treatment

Emerging technologies have significantly improved the diagnostic accuracy and management of ankylosing spondylitis. Imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are now routinely employed to detect early signs of inflammation and structural damage in the spine and sacroiliac joints. These high-resolution tools facilitate early diagnosis, which is crucial for initiating timely treatment.

Additionally, the integration of artificial intelligence (AI) and machine learning in image analysis has enhanced diagnostic precision. AI-driven tools are capable of identifying subtle pathological changes that might be overlooked by human evaluators, further supporting early and accurate diagnosis.

On the treatment front, advancements in biotechnology have led to the development of biological therapies-targeted drugs that address the specific immune mechanisms driving AS-related inflammation. TNF inhibitors have significantly improved patient outcomes by alleviating pain, stiffness, and inflammation. Furthermore, the emergence of biosimilars-cost-effective alternatives to biologic drugs-has broadened patient access to these life-changing treatments, especially in cost-sensitive markets.

Key Market Players

  • AbbVie, Inc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • UCB, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc

Report Scope:

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ankylosing Spondylitis Therapeutics Market, By Drug:

  • Cosentyx
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia

Ankylosing Spondylitis Therapeutics Market, By End Use:

  • Hospitals
  • Clinics
  • Others

Ankylosing Spondylitis Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.

Available Customizations:

Global Ankylosing Spondylitis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Ankylosing Spondylitis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
    • 5.2.2. By End Use (Hospitals, Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Ankylosing Spondylitis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug
        • 6.3.3.2.2. By End Use

7. Europe Ankylosing Spondylitis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug
        • 7.3.1.2.2. By End Use
    • 7.3.2. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug
        • 7.3.2.2.2. By End Use
    • 7.3.3. Italy Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug
        • 7.3.3.2.2. By End Use
    • 7.3.4. France Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug
        • 7.3.5.2.2. By End Use

8. Asia-Pacific Ankylosing Spondylitis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug
        • 8.3.5.2.2. By End Use

9. South America Ankylosing Spondylitis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Ankylosing Spondylitis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Ankylosing Spondylitis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. AbbVie, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Amgen, Inc.
  • 14.3. Pfizer, Inc.
  • 14.4. Novartis AG
  • 14.5. Eli Lilly and Company
  • 14.6. UCB, Inc.
  • 14.7. Johnson & Johnson Services, Inc.
  • 14.8. Merck & Co., Inc

15. Strategic Recommendations

16. About Us & Disclaimer